triple glp-1/gip/glucagon receptor agonist LY3437943, a novel glucagon, GIP, and GLP-1 for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism parkinson's disease triple agonist glp-1

HypothalamicPituitary Integration: GLP-1 neurons in the arcuate nucleus project to GnRH neurons, suggesting that GLP-1 signaling may influence gonadotropin secretion

GLP-1 medicines induce substantial metabolic improvements in the liver, with reduction in liver weight and lipid accumulation largely attributed to weight loss

GLP-1 receptor agonists and GLP-1/GIP combination therapies have become foundational treatments for type 2 diabetes and obesity

Metabolism (2016) 65(8):118395

As anyone whos ever struggled to maintain a healthy weight will confirm, its a lot easier (and more enjoyable) to gain weight than losing it

These include: Nausea Vomiting Diarrhoea Constipation Abdominal pain These side effects are typically mild to moderate, most common when starting the medication or increasing the dose, and often subside over time